212 related articles for article (PubMed ID: 2564204)
1. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
Szende B; Zalatnai A; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
[TBL] [Abstract][Full Text] [Related]
2. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
Paz-Bouza JI; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
[TBL] [Abstract][Full Text] [Related]
3. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
Zalatnai A; Schally AV
Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
Szende B; Srkalovic G; Schally AV; Lapis K; Groot K
Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
Szepeshazi K; Lapis K; Schally AV
Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045
[TBL] [Abstract][Full Text] [Related]
7. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
8. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.
Zalatnai A; Schally AV
Int J Pancreatol; 1989 Mar; 4(2):149-60. PubMed ID: 2566638
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):248-52. PubMed ID: 6141560
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
13. Membrane receptors for peptides in experimental and human pancreatic cancers.
Fekete M; Zalatnai A; Comaru-Schally AM; Schally AV
Pancreas; 1989; 4(5):521-8. PubMed ID: 2573055
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
Szepshazi K; Halmos G; Groot K; Schally AV
Int J Pancreatol; 1994; 16(2-3):141-9. PubMed ID: 7868940
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
Torres-Aleman I; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
[TBL] [Abstract][Full Text] [Related]
19. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
20. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]